171 related articles for article (PubMed ID: 38057434)
21. The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
Yamada I; Morizane C; Okusaka T; Mizusawa J; Kataoka T; Ueno M; Ikeda M; Okano N; Todaka A; Shimizu S; Mizuno N; Sekimoto M; Tobimatsu K; Yamaguchi H; Nishina T; Shirakawa H; Kojima Y; Oono T; Kawamoto Y; Furukawa M; Iwai T; Sudo K; Okamura K; Yamashita T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Sci Rep; 2022 Jan; 12(1):987. PubMed ID: 35046457
[TBL] [Abstract][Full Text] [Related]
22. Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy.
Wu CE; Huang WK; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34201707
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
[TBL] [Abstract][Full Text] [Related]
24. Durvalumab: A Review in Advanced Biliary Tract Cancer.
Fung S; Syed YY
Target Oncol; 2023 Nov; 18(6):965-972. PubMed ID: 37943483
[TBL] [Abstract][Full Text] [Related]
25. Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
Jung K; Park J; Jung JH; Lee JC; Kim J; Hwang JH
Gut Liver; 2022 Sep; 16(5):798-805. PubMed ID: 35000934
[TBL] [Abstract][Full Text] [Related]
26. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Phelip JM; Desrame J; Edeline J; Barbier E; Terrebonne E; Michel P; Perrier H; Dahan L; Bourgeois V; Akouz FK; Soularue E; Ly VL; Molin Y; Lecomte T; Ghiringhelli F; Coriat R; Louafi S; Neuzillet C; Manfredi S; Malka D;
J Clin Oncol; 2022 Jan; 40(3):262-271. PubMed ID: 34662180
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
[TBL] [Abstract][Full Text] [Related]
28. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
[TBL] [Abstract][Full Text] [Related]
29. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Choi IS; Kim KH; Lee JH; Suh KJ; Kim JW; Park JH; Kim YJ; Kim JS; Kim JH; Kim JW
Eur J Cancer; 2021 Sep; 154():288-295. PubMed ID: 34303267
[TBL] [Abstract][Full Text] [Related]
30. [Chemotherapy for Biliary Tract Cancer].
Woo SM
Korean J Gastroenterol; 2017 Mar; 69(3):172-176. PubMed ID: 28329919
[TBL] [Abstract][Full Text] [Related]
31. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
[TBL] [Abstract][Full Text] [Related]
32. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
[TBL] [Abstract][Full Text] [Related]
33. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
34. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Goyal L; Sirard C; Schrag M; Kagey MH; Eads JR; Stein S; El-Khoueiry AB; Manji GA; Abrams TA; Khorana AA; Miksad R; Mahalingam D; Zhu AX; Duda DG
Clin Cancer Res; 2020 Dec; 26(23):6158-6167. PubMed ID: 32878766
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.
Kobayashi S; Ueno M; Sugimori K; Morizane C; Kojima Y; Irie K; Goda Y; Morimoto M; Ohkawa S
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1189-1196. PubMed ID: 29071413
[TBL] [Abstract][Full Text] [Related]
37. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy.
Hamada T; Nakai Y; Yasunaga H; Isayama H; Matsui H; Takahara N; Sasaki T; Takagi K; Watanabe T; Yagioka H; Kogure H; Arizumi T; Yamamoto N; Ito Y; Hirano K; Tsujino T; Tada M; Koike K
Br J Cancer; 2014 Apr; 110(8):1943-9. PubMed ID: 24642625
[TBL] [Abstract][Full Text] [Related]
38. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.
Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Sasahira N; Hirano K; Tsujino T; Tada M; Omata M; Koike K
Invest New Drugs; 2011 Dec; 29(6):1488-93. PubMed ID: 20607585
[TBL] [Abstract][Full Text] [Related]
39. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
Zheng T; Jin J; Zhou L; Zhang Y
Oncol Res Treat; 2020; 43(9):460-469. PubMed ID: 32629449
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine alone or in combination with Cisplatin for advanced biliary tract carcinomas: an overview of clinical evidence.
Sun TT; Wang JL; Fang JY
Asian Pac J Cancer Prev; 2013; 14(2):877-83. PubMed ID: 23621255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
